Literature DB >> 3095477

Plasma metabolism of apolipoprotein A-IV in humans.

G Ghiselli, S Krishnan, Y Beigel, A M Gotto.   

Abstract

As assessed by molecular sieve chromatography and quantitation by a specific radioimmunoassay, apoA-IV is associated in plasma with the triglyceride-rich lipoproteins, to a high density lipoprotein (HDL) subfraction of smaller size than HDL3, and to the plasma lipoprotein-free fraction (LFF). In this study, the turnover of apoA-IV associated to the triglyceride-rich lipoproteins, HDL and LFF was investigated in vivo in normal volunteers. Human apoA-IV isolated from the thoracic duct lymph chylomicrons was radioiodinated and incubated with plasma withdrawn from normal volunteers after a fatty meal. Radioiodinated apoA-IV-labeled triglyceride-rich lipoproteins, HDL, and LFF were then isolated by chromatography on an AcA 34 column. Shortly after the injection of the radioiodinated apoA-IV-labeled triglyceride-rich lipoproteins, most of the radioactivity could be recovered in the HDL and LFF column fractions. On the other hand, when radioiodinated apoA-IV-labeled HDL or LFF were injected, the radioactivity remained with the originally injected fractions at all times. The residence time in plasma of 125I-labeled apoA-IV, when injected in association with HDL or LFF, was 1.61 and 0.55 days, respectively. When 125I-labeled apoA-IV was injected as a free protein, the radioactivity distributed rapidly among the three plasma pools in proportion to their mass. The overall fractional catabolic rate of apoA-IV in plasma was measured in the three normal subjects and averaged 1.56 pools per day. The mean degradation rate of apoA-IV was 8.69 mg/kg X day. The results are consistent with the conclusions that: apoA-IV is present in human plasma in three distinct metabolic pools; apoA-IV associated with the triglyceride-rich lipoproteins is a precursor to the apoA-IV HDL and LFF pools; apoA-IV in LFF is not a free protein and its turnover rate is faster than that of apoA-IV in HDL; since no transfer of apoA-IV from the HDL or the LFF occurs, these pools may represent a terminal pathway for the catabolism of apoA-IV; and the catabolism of apoA-IV in HDL is dissociated from that of apoA-I although both apoproteins may reside on the same lipoprotein particles.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3095477

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  21 in total

1.  Changes of genetic apolipoprotein phenotypes caused by liver transplantation. Implications for apolipoprotein synthesis.

Authors:  H G Kraft; H J Menzel; F Hoppichler; W Vogel; G Utermann
Journal:  J Clin Invest       Date:  1989-01       Impact factor: 14.808

2.  Static and turnover kinetic measurement of protein biomarkers involved in triglyceride metabolism including apoB48 and apoA5 by LC/MS/MS.

Authors:  Yi Pan; Haihong Zhou; Ablatt Mahsut; Rory J Rohm; Olga Berejnaia; Olga Price; Ying Chen; Jose Castro-Perez; Michael E Lassman; David McLaren; James Conway; Kristian K Jensen; Tiffany Thomas; Gissette Reyes-Soffer; Henry N Ginsberg; David E Gutstein; Michele Cleary; Stephen F Previs; Thomas P Roddy
Journal:  J Lipid Res       Date:  2014-04-02       Impact factor: 5.922

3.  Reduced aortic lesions and elevated high density lipoprotein levels in transgenic mice overexpressing mouse apolipoprotein A-IV.

Authors:  R D Cohen; L W Castellani; J H Qiao; B J Van Lenten; A J Lusis; K Reue
Journal:  J Clin Invest       Date:  1997-04-15       Impact factor: 14.808

4.  Isolation of a high-density-lipoprotein conversion factor from human plasma. A possible role of apolipoprotein A-IV as its activator.

Authors:  P J Barter; O V Rajaram; L B Chang; K A Rye; P Gambert; L Lagrost; C Ehnholm; N H Fidge
Journal:  Biochem J       Date:  1988-08-15       Impact factor: 3.857

5.  Apolipoprotein A-IV improves glucose homeostasis by enhancing insulin secretion.

Authors:  Fei Wang; Alison B Kohan; Tammy L Kindel; Kathryn L Corbin; Craig S Nunemaker; Silvana Obici; Stephen C Woods; W Sean Davidson; Patrick Tso
Journal:  Proc Natl Acad Sci U S A       Date:  2012-05-22       Impact factor: 11.205

6.  Multiple apolipoprotein kinetics measured in human HDL by high-resolution/accurate mass parallel reaction monitoring.

Authors:  Sasha A Singh; Allison B Andraski; Brett Pieper; Wilson Goh; Carlos O Mendivil; Frank M Sacks; Masanori Aikawa
Journal:  J Lipid Res       Date:  2016-02-09       Impact factor: 5.922

7.  Apolipoprotein A-IV inhibits experimental colitis.

Authors:  Thorsten Vowinkel; Mikiji Mori; Christian F Krieglstein; Janice Russell; Fumito Saijo; Sulaiman Bharwani; Richard H Turnage; W Sean Davidson; Patrick Tso; D Neil Granger; Theodore J Kalogeris
Journal:  J Clin Invest       Date:  2004-07       Impact factor: 14.808

Review 8.  Apolipoprotein A-IV: a protein intimately involved in metabolism.

Authors:  Fei Wang; Alison B Kohan; Chun-Min Lo; Min Liu; Philip Howles; Patrick Tso
Journal:  J Lipid Res       Date:  2015-02-01       Impact factor: 5.922

9.  Intestinal expression of human apolipoprotein A-IV in transgenic mice fails to influence dietary lipid absorption or feeding behavior.

Authors:  K Aalto-Setälä; C L Bisgaier; A Ho; K A Kieft; M G Traber; H J Kayden; R Ramakrishnan; A Walsh; A D Essenburg; J L Breslow
Journal:  J Clin Invest       Date:  1994-04       Impact factor: 14.808

10.  Rapid in vivo transport and catabolism of human apolipoprotein A-IV-1 and slower catabolism of the apoA-IV-2 isoprotein.

Authors:  D J Rader; J Schäfer; P Lohse; B Verges; M Kindt; L A Zech; A Steinmetz; H B Brewer
Journal:  J Clin Invest       Date:  1993-08       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.